Lynparza approved in Japan as adjuvant treatment for patients with BRCA-mutated HER2-negative high-risk early breast cancer
First and only approved medicine targeting BRCA mutations in early breast cancer.AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the adjuvant treatment of patients with BRCA-mutated (BRCAm), HER2-negative early breast cancer at high risk of recurrence. This approval by the Japanese Ministry of Health, Labour, and Welfare was based on results from the OlympiA Phase III trial